Category: Arch Therapeutics
MassDevice.com asks medical device CEOs about the key issues of 2014 and what's ahead for the New Year.
As 2014 draws to a close, MassDevice.com asked several medical device company CEOs for their takes on 2014 and what they're looking for in 2015.
We wanted to get their views on the major trends seen in medtech this year, including the red-hot M&A and IPO scenes, the medical device tax, the regulatory environment in the U.S., and more.
Bruce Shook, the co-founder & former CEO of Neuronetics and the ex-president of Abiomed, is named CEO of Intact Vascular.
Intact Vascular said yesterday that it named medical device veteran Bruce Shook as its new president & CEO.
Here's a look at some of the top personnel stories for medical device companies this week.
Malta regulators announced this week that healthcare titan Baxter plans to add 30 additional jobs in the country.
Stephen Fanning, the former CEO of Solta Medical, is Z-Medica's new chief.
Z-Medica said it named Stephen Fanning, the former CEO of Solta Medical, to be its new chief executive.
Wallingford, Conn.-based Z-Medica is developing blood clotting technologies it calls QuikClot.
Arch Therapeutics hits its $2.9 million funding goal after announcing a private stock placement late last year.
Arch Therapeutics hit its nearly $2.9 million target with a private placement announced late last year.
Massachusetts-based Arch Therapeutics hopes to sell over 11 million shares to raise close to $3 million in support of its medical sealants and hemostasis products.
Arch Therapeutics launched a private placement fundraising effort, offering 11.4 million shares of common stock in hopes of raising $2.9 million.
Arch Therapeutics reports a $7.3 million financing through a share-swap related to its reverse merger with Arch Biosurgery, which marked the Arch Therapeutics’ transformation into a life sciences company.
Cambridge, Mass.-based device company Arch Therapeutics raised $7.3 million through a stock trade in connection with its reverse merger with Arch Biosurgery.
Arch Therapeutics issued shares of its common stock in exchange for cancellation of equity or rights to acquire equity in Arch Biosurgery, according to a regulatory filing.